Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of EBT readings, the most recent being -$11.9 million for Q4 2025.

  • On a quarterly basis, EBT rose 47.53% to -$11.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$72.8 million, a 31.66% increase, with the full-year FY2025 number at -$83.5 million, up 29.07% from a year prior.
  • EBT hit -$11.9 million in Q4 2025 for Enanta Pharmaceuticals, up from -$18.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$11.9 million in Q4 2025 to a low of -$37.6 million in Q1 2023.
  • Median EBT over the past 5 years was -$29.4 million (2023), compared with a mean of -$28.1 million.
  • Biggest five-year swings in EBT: crashed 193.75% in 2021 and later surged 47.53% in 2025.
  • Enanta Pharmaceuticals' EBT stood at -$30.2 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then decreased by 17.26% to -$34.0 million in 2023, then surged by 33.27% to -$22.7 million in 2024, then surged by 47.53% to -$11.9 million in 2025.
  • The last three reported values for EBT were -$11.9 million (Q4 2025), -$18.7 million (Q3 2025), and -$18.2 million (Q2 2025) per Business Quant data.